ストックスクリーナーアプリを入手
76.00
0.71%
-0.54
アフターアワーズ：
76.00
Ani Pharmaceuticals Inc (ANIP) 最新ニュース
The Top 5 Analyst Questions From ANI Pharmaceuticals’s Q2 Earnings Call - Yahoo Finance
ANI Pharmaceuticals (ANIP) Could Be 34% Undervalued As Earnings And Guidance Hold - Sahm
Winners And Losers Of Q2: ANI Pharmaceuticals (NASDAQ:ANIP) Vs The Rest Of The Generic Pharmaceuticals Stocks - Yahoo Finance
Walleye Capital LLC Buys Shares of 106,112 ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk? - TradingView
ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth - Yahoo Finance
ANI Pharmaceuticals (ANIP) Insider Sell: SR. VP, GENERAL COUNSEL & SEC. Meredith Cook Sells 500 Shares - GuruFocus
ANI Pharmaceuticals Senior VP Meredith Cook Sells 500 Shares via 10b5-1 Trading Plan - Kalkine Media
Meredith Cook Sells 500 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock - MarketBeat
ANI Pharmaceuticals (ANIP) counsel Meredith Cook sells 500 shares under 10b5-1 plan - Stock Titan
Amundi Has $352,000 Holdings in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
ANI Pharmaceuticals Inc (ANIP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Ani Pharmaceuticals SVP Ori Gutwerg sells $243,474 in common stock. By Investing.com - Investing.com Australia
Ori Gutwerg Sells 3,162 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock - MarketBeat
Ani Pharmaceuticals SVP Ori Gutwerg sells $243,474 in common stock. - Investing.com
ANI Pharma SVP, Generics Ori Gutwerg reports sale of 3,162 common shares worth $243,474 - Bitget
ANI Pharmaceuticals (ANIP) SVP Ori Gutwerg sells 3,162 shares at $77 - Stock Titan
ANIP Q2 Deep Dive: Rare Disease Expansion Drives Growth Amid Guidance Recalibration - Yahoo Finance
Analysts cut ANI Pharmaceuticals targets despite Q2 earnings beat - scanx.trade
Guggenheim cuts ANI Pharmaceuticals stock price target on Cortrophin guidance - Investing.com
Canaccord Genuity Group Cuts ANI Pharmaceuticals (NASDAQ:ANIP) Price Target to $90.00 - MarketBeat
Canaccord cuts ANI Pharmaceuticals stock price target on Cortrophin miss By Investing.com - Investing.com Canada
ANI Pharmaceuticals (NASDAQ:ANIP): What Could Today Reveal? - Kalkine Media
ANI Pharmaceuticals (ANIP) Could Be 31% Undervalued On Strong Q2 Results And Guidance Reset - finance.yahoo.com
ANI Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:ANIP) 2026-08-08 - Seeking Alpha
Earnings Surge And Reaffirmed 2026 Outlook Might Change The Case For Investing In ANI Pharmaceuticals (ANIP) - Sahm
ANI Pharmaceuticals (NASDAQ:ANIP) Stock Rating Lowered by Wall Street Zen - MarketBeat
ANI Pharmaceuticals (NASDAQ:ANIP) Announces Earnings Results - MarketBeat
ANI Pharmaceuticals’s (NASDAQ:ANIP) Q2 CY2026 Sales Beat Estimates But Stock Drops On Weak Guidance - webull.com
ANI Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
ANI Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $109.12, Implies 32% Upside - TradingView
Earnings call transcript: ANI Pharmaceuticals beats Q2 2026 estimates, shares fall premarket - Investing.com
ANI Pharmaceuticals Q2 2026 slides: record results, gout expansion underway - Investing.com Nigeria
ANI Pharmaceuticals Inc (ANIP) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic ... - Yahoo Finance
ANI Pharmaceuticals Announces Q2 2026 Earnings and Releases Updated Investor Presentation - Kalkine Media
ANI Pharmaceuticals, Inc (ANIP) Q2 2026 Earnings Call Transcript - AlphaStreet
ANI Pharmaceuticals Q2 2026 Earnings Call Transcript - MarketBeat
ANI Pharmaceuticals (NASDAQ:ANIP) Guidance Signals Fresh Momentum - Kalkine Media
ANI Pharmaceuticals (NASDAQ:ANIP) Shares Gap DownHere's Why - marketbeat.com
ANI Pharmaceuticals Q2 Earnings Call Highlights - marketbeat.com
ANI Pharmaceuticals Shares Slide Despite Earnings Beat After Cortrophin Outlook Cut - Yahoo Finance
ANI Pharmaceuticals, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
ANI Pharmaceuticals (NASDAQ:ANIP) Tumbles on Weak Guidance Despite Q2 EPS Beat - ChartMill
ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Beat Estimates - Yahoo! Finance Canada
ANI Pharmaceuticals posts 25.9% revenue growth in Q2 2026, driven by Cortrophin Gel sales surge. - Pluang
ANI Pharmaceuticals Inc. R (BSFA.F) Q2 FY2026 earnings call transcript - Yahoo Finance
ANI Pharmaceuticals stock falls 7% despite second quarter beat By Investing.com - Investing.com Canada
ANI Pharmaceuticals stock falls 7% despite second quarter beat - Investing.com
ANI PHARMACEUTICALS ($ANIP) Releases Q2 2026 Earnings - Quiver Quantitative
ANI Pharmaceuticals (NASDAQ:ANIP) Releases FY 2026 Earnings Guidance - MarketBeat
ANI Pharmaceuticals Q2 Adjusted Earnings, Revenue Rise - marketscreener.com
ANI Pharmaceuticals 2026: Revenue $266.04M, EPS $1.05— 10-Q Summary - TradingView
ANI Pharmaceuticals Q2 adjusted EPS beats on increased volume in specialty areas - TradingView
ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results - manilatimes.net
ANI Pharmaceuticals Reports Second-Quarter 2026 Results, Raises Cortrophin Gel Guidance and Reaffirms Full-Year Outlook - Quiver Quantitative
(ANIP) ANI Pharmaceuticals Expects 2026 Net Revenue Range $1.08B$1.14B, vs. FactSet Est of $1.12B - marketscreener.com
(ANIP) ANI Pharmaceuticals Expects 2026 Adjusted EPS Range $9.19$9.69, vs. FactSet Est of $9.45 - marketscreener.com
Earnings Flash (ANIP) ANI Pharmaceuticals, Inc. Reports Q2 Revenue $266.0M, vs. FactSet Est of $260.1M - marketscreener.com
BRIEF-ANI Pharmaceuticals Q2 Adjusted EPS USD 2.21 Vs. IBES Estimate USD 2.05 - TradingView
Press Release: ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results - Moomoo
ANI Pharma Q2 FY26 GAAP net income climbs 203.5% to $24.7 million; net revenues rise 25.9% to $266 million - Bitget
ANI Pharmaceuticals earnings on deck as rare disease shift accelerates By Investing.com - Investing.com Nigeria
1.61%
1.30%
大文字化:
|
ボリューム (24 時間):